Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmuneRegen BioSciences, a wholly owned biotechnology product development and licensing subsidiary of IR BioSciences Holdings, has reported positive study findings on its drug candidate Homspera.
Subscribe to our email newsletter
The results show Homspera to be effective in stimulating human, adult, blood-forming stem cells (hematopoietic stem cells), which have previously been shown to be capable of becoming blood cells that are vital to the body’s immune system. This suggests a role for Homspera in strengthening the human immune system.
The study by HemoGenix, a research laboratory, found ImmuneRegen’s Homspera not only increased the number of early-stage white blood cells by up to 200% when compared to controls, but also produced this effect at surprisingly low concentrations, the company said.
Kasey Benson, ImmuneRegen’s scientific director, said: “These results help explain the myriad of successful animal studies previously reported for Homspera in widely diverse areas of health-related fields, including Homspera’s positive results in influenza therapy, combating the effects of radiation exposure and enhancing the efficacy of vaccines (vaccine adjuvant activity). These findings from adult human stem cells suggest that Homspera could also produce positive effects clinically.”